-
EP4313953
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4313953
| EP4313953 - SELECTIVE ANGIOTENSIN II RECEPTOR LIGANDS [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 05.01.2024 Database last updated on 02.09.2024 | |
| Former | The international publication has been made Status updated on 30.09.2022 | ||
| Former | unknown Status updated on 13.04.2022 | Most recent event Tooltip | 24.05.2024 | Change: Validation states | published on 26.06.2024 [2024/26] | 24.05.2024 | Change - extension states | published on 26.06.2024 [2024/26] | Applicant(s) | For all designated states Vicore Pharma AB Kornhamnstorg 53 111 27 Stockholm / SE | [2024/06] | Inventor(s) | 01 /
FEX, Tomas 431 83 Mölndal / SE | 02 /
OHLSSON, Bengt 431 83 Mölndal / SE | 03 /
HALLBERG, Anders 753 12 Uppsala / SE | 04 /
LARHED, Mats 752 39 Uppsala / SE | [2024/06] | Representative(s) | Potter Clarkson Chapel Quarter Mount Street Nottingham NG1 6HQ / GB | [2024/06] | Application number, filing date | 22714509.1 | 23.03.2022 | [2024/06] | WO2022GB50725 | Priority number, date | GB20210004040 | 23.03.2021 Original published format: GB 202104040 | GB20210013583 | 23.09.2021 Original published format: GB 202113583 | [2024/06] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2022200785 | Date: | 29.09.2022 | Language: | EN | [2022/39] | Type: | A1 Application with search report | No.: | EP4313953 | Date: | 07.02.2024 | Language: | EN | The application published by WIPO in one of the EPO official languages on 29.09.2022 takes the place of the publication of the European patent application. | [2024/06] | Search report(s) | International search report - published on: | EP | 29.09.2022 | Classification | IPC: | C07D233/60, C07D401/12, C07D409/12, C07D417/14, A61P9/00, A61P11/00, A61P13/12, A61P37/00, A61K31/4164, A61K31/4178 | [2024/06] | CPC: |
A61P13/12 (EP);
C07D417/14 (EP,US);
A61P11/00 (EP);
A61P37/00 (EP);
A61P9/00 (EP);
C07D233/58 (US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2024/06] | Title | German: | SELEKTIVE ANGIOTENSIN II REZEPTORLIGANDEN | [2024/06] | English: | SELECTIVE ANGIOTENSIN II RECEPTOR LIGANDS | [2024/06] | French: | LIGANDS SÉLECTIFS DU RÉCEPTEUR DE L'ANGIOTENSINE II | [2024/06] | Entry into regional phase | 18.10.2023 | National basic fee paid | 18.10.2023 | Designation fee(s) paid | 18.10.2023 | Examination fee paid | Examination procedure | 18.10.2023 | Examination requested [2024/06] | 18.10.2023 | Date on which the examining division has become responsible | 23.04.2024 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 04.01.2024 | Renewal fee patent year 03 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [Y]EP0479479 (MERCK & CO INC [US]); | [YD]WO02096883 (VICORE PHARMA AB [SE], et al); | [YP]WO2021053344 (VICORE PHARMA AB [SE]); | [YP]WO2021186180 (VICORE PHARMA AB [SE]); | [XP]WO2021186185 (VICORE PHARMA AB [SE]); | [YP]WO2022049372 (VICORE PHARMA AB [SE]); | by applicant | US5312820 | GB2281298 | WO9943339 | WO02096883 | WO2004046141 | US2004167176 | US2012035232 | WO2016092329 | WO2016107879 | WO2016139475 | WO2017221012 | WO2019008393 |